GeneHealth - Your precision medicine

Infantile Myofibromatosis

Disease Details

Family Health Simplified

Buy Membership

Description: Infantile myofibromatosis is a rare disorder characterized by the formation of benign tumors in the skin, muscle, bones, or internal organs, primarily affecting infants and young children.
Type: Infantile myofibromatosis is a rare benign tumor disorder that primarily affects infants and young children. It typically manifests as single or multiple nodules in the skin, muscles, bones, or internal organs.

Type of Genetic Transmission: Infantile myofibromatosis can be inherited in an autosomal dominant manner. However, many cases appear to occur sporadically with no clear family history. Mutations in the PDGFRB and NOTCH3 genes have been associated with familial cases.
Signs And Symptoms: For infantile myofibromatosis, here are the key points:

**Signs and Symptoms:**
1. **Tumor Formation:** The primary sign is the development of benign (non-cancerous) tumors in the skin, muscles, bones, and sometimes internal organs.
2. **Skin Tumors:** These often present as firm, nodular masses that may be skin-colored or have a bluish hue.
3. **Muscle and Bone Involvement:** Tumors in these areas can cause pain or discomfort and may restrict movement.
4. **Internal Organ Tumors:** When tumors are present in vital organs, such as the lungs or gastrointestinal tract, symptoms can be more severe and include respiratory distress or gastrointestinal issues.
5. **Asymptomatic Lesions:** Some tumors may not cause any symptoms and are only detected through imaging studies.

**NAN:**
It seems you intended to ask about another specific detail, but "nan" is not clear. If you could provide more context or clarify, I can offer more precise information.
Prognosis: Infantile myofibromatosis typically has a generally good prognosis, especially for solitary lesions that are localized and can be treated effectively, often with surgical excision. In cases where multiple lesions are present, the prognosis can vary and may depend on the extent and location of the tumors. Lesions that involve vital organs can lead to complications. Nan refers to "Not a Number" often implying missing or undefined data, so more specific prognostic details would require more precise information about individual cases.
Onset: The onset of infantile myofibromatosis typically occurs in infancy or early childhood. It is characterized by the development of benign tumors in the skin, muscles, bones, and sometimes internal organs.
Prevalence: The prevalence of infantile myofibromatosis is estimated to be approximately 1 in 150,000 to 1 in 400,000 live births.
Epidemiology: Infantile myofibromatosis is a rare disorder that typically presents in infancy or early childhood. The exact incidence is not well established due to its rarity, but it is one of the most common types of fibrous tumors in infants. It affects both genders almost equally. The condition can present as solitary or multicentric lesions, with the solitary form generally having a better prognosis.
Intractability: Infantile myofibromatosis is not typically considered intractable. This rare condition usually involves the development of benign tumors in the skin, muscles, bones, and sometimes internal organs. Many cases are solitary and may resolve spontaneously or with minimal intervention. However, in more severe cases with multiple lesions or vital organ involvement, treatment such as surgery, medication, or other therapies may be required. The prognosis can vary depending on the extent and location of the tumors.
Disease Severity: Infantile myofibromatosis is a rare benign disorder characterized by the development of benign fibrous tumors in infants and young children. The disease can vary in severity:

1. **Localized Form**: Generally involves single or multiple tumors in the skin, muscles, bones, or viscera. This form usually has a good prognosis and may spontaneously regress without treatment.

2. **Generalized Form**: Involves multiple organs including life-threatening visceral involvement such as the lungs, gastrointestinal tract, or cardiovascular system. This form can be severe and may require aggressive treatment, though it carries a higher risk of complications.

Overall, the prognosis and severity of the disease depend on the extent and location of tumor involvement.
Healthcare Professionals: Disease Ontology ID - DOID:0080109
Pathophysiology: Infantile myofibromatosis is a rare fibrous disorder that typically presents in infants and young children. It is characterized by the formation of benign tumors in the skin, muscle, bone, and sometimes internal organs.

Pathophysiology:
- It involves the proliferation of myofibroblasts, which are cells that have properties of both smooth muscle cells and fibroblasts.
- The condition can be either solitary, affecting a single site, or multicentric, involving multiple sites.
- Genetic mutations, particularly in the PDGFRB gene, have been implicated in some familial cases.
- The exact mechanism of how these mutations lead to tumor development is not fully understood, but it likely involves abnormal signaling pathways that control cell growth and differentiation.

Treatment and prognosis vary depending on the number of tumors and their locations. Solitary lesions often spontaneously regress, while multicentric forms with visceral involvement may require more intensive management.
Carrier Status: Infantile myofibromatosis is typically not inherited in a carrier status manner since it is most often sporadic. However, in rare familial cases, it can follow an autosomal dominant or autosomal recessive pattern.
Mechanism: Infantile myofibromatosis is a rare disorder characterized by the formation of benign tumors in the skin, muscle, and, in some cases, internal organs. The exact mechanism of disease development is not fully understood but involves the dysregulation of cell growth.

**Molecular Mechanisms:**

1. **Genetic Mutations**: Mutations in two genes, PDGFRB (platelet-derived growth factor receptor beta) and NOTCH3, have been implicated in the pathogenesis of infantile myofibromatosis. PDGFRB mutations are more commonly associated with familial cases and lead to abnormal signaling that promotes cell proliferation.

2. **PDGFRB Pathway**: PDGFRB encodes a cell surface tyrosine kinase receptor. Mutations causing constitutive activation of this receptor can lead to uncontrolled cellular growth and formation of myofibromas. Overactive PDGFRB signaling promotes cellular proliferation and survival pathways.

3. **NOTCH3 Pathway**: NOTCH3 is involved in cell fate determination, differentiation, and proliferation. Mutations here disrupt normal signaling and contribute to abnormal cell growth behavior characteristic of myofibromatosis.

These genetic alterations disrupt normal cellular signaling pathways, leading to the development of multiple fibrous tumors in affected infants. Further research is ongoing to fully elucidate all the molecular pathways involved.
Treatment: Treatment for infantile myofibromatosis primarily depends on the number, size, and location of the tumors, as well as the presence of symptoms. In many cases, solitary tumors may regress spontaneously without intervention. For more extensive disease or symptomatic cases, treatment options include:

1. **Observation**: Monitoring the condition if it is asymptomatic and not progressing.
2. **Surgery**: Removal of tumors causing symptoms or complications.
3. **Medication**: Use of systemic therapies such as corticosteroids, chemotherapy, or targeted therapies in cases where surgery is not feasible or if there are multiple lesions.

Consultation with a pediatric oncologist or specialist familiar with this condition is essential for personalized treatment planning.
Compassionate Use Treatment: Infantile myofibromatosis (IM) is a rare disorder characterized by the development of benign tumors in the skin, muscles, bones, and, occasionally, internal organs. Due to its rarity, there are limited standard treatments, and management often depends on the individual patient's condition and the severity of the disease.

### Compassionate Use Treatment and Experimental Treatments:
- **Chemotherapy**: Some patients with unresectable or life-threatening infantile myofibromatosis have been treated with chemotherapeutic agents such as vinblastine and methotrexate. These are not standard therapies but have been used in specific, severe cases.

- **Targeted Therapy**: In some experimental settings, targeted therapies like imatinib have been explored due to their action mechanism on similar pathways involved in the disease.

- **Immunotherapy**: The use of agents like interferon-alpha has shown some promise in anecdotal cases but is not a standard treatment.

- **Clinical Trials**: Participation in clinical trials can offer access to new and potentially effective therapies under investigation.

It's important to consult with specialists in pediatric oncology and those experienced with rare diseases to explore these treatment options comprehensively and assess their suitability based on the individual case of the patient.
Lifestyle Recommendations: Lifestyle recommendations for infantile myofibromatosis primarily focus on managing symptoms and maintaining overall health. Since infantile myofibromatosis can vary significantly in severity and presentation, it's important to work closely with healthcare providers for personalized care. General recommendations include:

1. **Regular Medical Follow-ups**: Ensure consistent check-ups with a pediatrician and relevant specialists to monitor growth and development, as well as the progression of any myofibromas.
2. **Balanced Diet**: Provide a well-balanced, nutritious diet to support overall growth and immune function.
3. **Physical Activity**: Encourage age-appropriate physical activity as tolerated; avoid activities that could cause trauma to affected areas.
4. **Infection Prevention**: Practice good hygiene and take precautions to prevent infections, which can be critical if the condition affects vital organs.
5. **Pain Management**: Work with healthcare providers to manage any pain or discomfort resulting from tumors.
6. **Emotional Support**: Provide emotional and psychological support to the child and family, as chronic conditions can be challenging.

Always consult with healthcare providers to tailor recommendations to the child's specific needs and condition.
Medication: Infantile myofibromatosis is a rare disorder characterized by the development of benign tumors in the skin, muscles, bones, and sometimes internal organs of infants and young children. There is no standard medication specifically approved for treating this condition. Management typically depends on the severity and location of the tumors:

1. **Observation**: In cases where the tumors are not causing significant symptoms, regular monitoring may be sufficient, as some lesions can regress spontaneously without treatment.

2. **Surgery**: Surgical removal may be necessary if the tumors are causing functional impairment, pain, or are cosmetically concerning.

3. **Other Interventions**: For more aggressive or widespread disease, treatment may include chemotherapy or targeted therapies, although these approaches are less commonly used and would be considered on a case-by-case basis.

Consultation with a pediatric specialist, such as a pediatric oncologist or dermatologist, is essential for managing this condition.
Repurposable Drugs: Infantile myofibromatosis is a rare disorder characterized by the development of benign myofibromas in the skin, muscle, bone, and sometimes internal organs. There are no specific FDA-approved treatments for infantile myofibromatosis, but various therapies might be repurposed based on symptom management and clinical experience. Some of the repurposable drugs include:

1. **Sirolimus (Rapamycin)**: This mTOR inhibitor has shown promise in cases where there are multiple lesions or when vital structures are involved.
2. **Vismodegib**: An inhibitor of the Hedgehog signaling pathway, which has been explored in certain cases involving refractory fibromatosis.
3. **Imatinib**: A tyrosine kinase inhibitor that has been used successfully in some other benign tumors and might be considered.
4. **Methotrexate and Vinblastine**: Combined chemotherapy regimens have been used in some severe or life-threatening cases.

Treatment typically depends on the number, size, and location of the myofibromas and whether they are causing symptoms or complications.
Metabolites: Infantile myofibromatosis is a rare disorder characterized by the development of benign, fibrous tumors in the skin, muscle, bone, and sometimes internal organs in infants. There isn't specific information typically linked to unique metabolites directly associated with infantile myofibromatosis. Diagnosis is primarily based on clinical examination, imaging, and histological analysis of the tumors.
Nutraceuticals: There is no substantial evidence supporting the use of nutraceuticals specifically for the treatment or management of infantile myofibromatosis. It is important to consult healthcare professionals for appropriate diagnosis and treatment options for this condition.
Peptides: Infantile myofibromatosis is a rare disorder characterized by the development of benign fibrous tumors in the skin, muscle, bones, or internal organs, primarily affecting infants and young children. Current research and treatment options do not specifically highlight a role for peptides or nanotechnology (represented by "nan") in the management or understanding of this disease.

Management typically involves surgical removal of the tumors if they cause functional impairment or significant symptoms. In many cases, these tumors may regress spontaneously without intervention.